Nanjing Vazyme Biotech Co Ltd Asset Resilience Ratio

Latest as of June 2026: 45.03%

Nanjing Vazyme Biotech Co Ltd asset resilience ratio. Nanjing Vazyme Biotech Co Ltd (688105) has an Asset Resilience Ratio of 45.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688105 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥2.09 Billion
≈ $305.17 Million USD Cash + Short-term Investments

Total Assets

CN¥4.63 Billion
≈ $677.71 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Nanjing Vazyme Biotech Co Ltd (2019–2025)

Asset resilience ratio of Nanjing Vazyme Biotech Co Ltd from 2019 to 2025. This chart shows how Nanjing Vazyme Biotech Co Ltd's Asset Resilience Ratio has changed over time. Read Nanjing Vazyme Biotech Co Ltd (688105) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Nanjing Vazyme Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Nanjing Vazyme Biotech Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.09 Billion 45.03%
Total Liquid Assets CN¥2.09 Billion 45.03%

Asset Resilience Insights

  • Very High Liquidity: Nanjing Vazyme Biotech Co Ltd maintains exceptional liquid asset reserves at 45.03% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Nanjing Vazyme Biotech Co Ltd Industry Peers by Asset Resilience Ratio

Compare Nanjing Vazyme Biotech Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%

Nanjing Vazyme Biotech Co Ltd Asset Resilience Ratio by Year (2019–2025)

Nanjing Vazyme Biotech Co Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Nanjing Vazyme Biotech Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 40.76% CN¥2.05 Billion
≈ $299.86 Million
CN¥5.03 Billion
≈ $735.75 Million
-3.26pp
2024-12-31 44.01% CN¥2.22 Billion
≈ $325.15 Million
CN¥5.05 Billion
≈ $738.78 Million
+17.66pp
2023-12-31 26.35% CN¥1.51 Billion
≈ $221.55 Million
CN¥5.75 Billion
≈ $840.85 Million
-2.28pp
2022-12-31 28.63% CN¥1.72 Billion
≈ $251.58 Million
CN¥6.01 Billion
≈ $878.75 Million
-14.26pp
2021-12-31 42.89% CN¥1.98 Billion
≈ $289.13 Million
CN¥4.61 Billion
≈ $674.17 Million
-6.48pp
2020-12-31 49.37% CN¥795.65 Million
≈ $116.43 Million
CN¥1.61 Billion
≈ $235.83 Million
+49.35pp
2019-12-31 0.02% CN¥50.00K
≈ $7.32K
CN¥324.33 Million
≈ $47.46 Million
--
pp = percentage points

About Nanjing Vazyme Biotech Co Ltd

SHG:688105 China Biotechnology
Market Cap
$1.68 Billion
CN¥11.49 Billion CNY
Market Cap Rank
#6532 Global
#1285 in China
Share Price
CN¥22.22
Change (1 day)
-7.03%
52-Week Range
CN¥13.14 - CN¥27.59
All Time High
CN¥119.29
About

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more